Josef H Von Rickenbach
CIK 1007706 · Chairman & CEO · last filed 2026-05-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRXL price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
WALTHAM, MA 02451-1163
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| RNTX | Director | 58,014 | $0.58 | $33.8K | $49.6K | 2 | 2026-05-28 |
| Rein Therapeutics, Inc. (ALRN) Delisted | Director | 22,273 | $2.11 | $47.0K | $400.3K | 13 | 2024-12-06 |
| Virgin Orbit Holdings, Inc. (VORBW) Delisted | 125,000 | $0.01 | $875 | $0 | 1 | 2022-01-03 | |
| PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Chairman & CEO | 503,329 | — | — | -$28.55M | 85 | 2017-09-18 |
Recent Filings · Page 2 of 11
102 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-09 | Rein Therapeutics, Inc. (ALRN) Delisted | Buy (P) | +227,272 | $250.0K | EDGAR |
| 2019-09-16 | Rein Therapeutics, Inc. (ALRN) Delisted | Buy (P) | +113,145 | $110.5K | EDGAR |
| 2019-09-05 | Rein Therapeutics, Inc. (ALRN) Delisted | Buy (P) | +23,225 | $16.6K | EDGAR |
| 2019-09-04 | Rein Therapeutics, Inc. (ALRN) Delisted | Buy (P) | +28,466 | $20.4K | EDGAR |
| 2019-09-03 | Rein Therapeutics, Inc. (ALRN) Delisted | Buy (P) | +3,600 | $2.8K | EDGAR |
| 2019-06-24 | Rein Therapeutics, Inc. (ALRN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-10-04 | — | Mixed | −503,329 | $0 | |
| 2017-09-18 | PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Tax (F) | −4,642 | -$408.2K | EDGAR |
| 2017-09-12 | PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Mixed | −28,889 | -$1.35M | EDGAR |
| 2016-09-16 | PAREXEL INTERNATIONAL CORP (PRXL) Delisted | Grant (A) | +29,600 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.